Browsing by Author "Erdur, Fatih Mehmet"

Now showing 1 - 7 of 7

Azigos Vein: Is It a Malposition or an Alternative
(Turk Nefroloji Diyaliz Transplantasyon dergisi, 2011) Emre, Habib; Soyoral, Yasemin Usul; Begenik, Huseyin; Demirkiran, Davut; Erdur, Fatih Mehmet; Gumrukcuoglu, Hasan Ali; Erkoc, Reha
Use of a temporary central venous catheter is common practice in hemodialysis therapy. One of the most common complications of central venous catheterization is catheter malposition. Cannulation of the azygos vein (particularly the azygos arch) is a rare but hazardous catheter malposition that carries a substantial risk of perforation, thrombosis and vascular stenosis. On the other hand, the azygos vein can be used for vascular access in patients whose superior vena cava and inferior vena cava are thrombosed. We present a case where the required blood flow for hemodialysis was provided by a dilated azygos vein due to superior vena cava obstruction.
Fenofibrate-Induced Rhabdomyolysis in a Patient With Chronic Renal Failure Due To Nephrotic Syndrome: a Rare Case Report
(Pergamon-elsevier Science Ltd, 2012) Erdur, Fatih Mehmet; Soyoral, Yasemin Usul; Emre, Habib; Begenik, Huseyin; Canbaz, Esra Turan; Erkoc, Reha
Objectives: Fenofibrate is a fibric acid derivative that is used alone or combination with statins in the treatment of hyperlipidemia. These drugs have potential risks, including rhabdomyolysis and acute renal failure. Despite reports of rhabdomyolysis with the use of fenofibrate alone or with statin-fibrate combinations, there have been no cases of rhabdomyolysis described when fenofibrate was used alone to treat patients with chronic renal failure owing to nephrotic syndrome. Design and methods: We report on a 26-year-old male who presented with fenofibrate-induced rhabdomyolysis with chronic renal failure due to nephrotic syndrome. Results: After the discontinuation of fenofibrate, the patient was treated with intravenous fluid replacement and urine alkalization. Subsequently, his clinical and biochemical findings improved. Conclusions: Before starting fenofibrate therapy, the causes of secondary hyperlipidemia, especially nephrotic syndrome, should be investigated. In the presence of chronic renal failure and hypoalbuminemia, the fenofibrate dose should be adjusted. Physicians should be aware of the potential toxicities of fenofibrate, and patients should be informed about its potential side effects. (C) 2011 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
Hepatic Encephalopathy in Connection With Budd-Chiari Syndrome Due To Infection With Echinococcus Multilocularis: a Case Report
(Elmer Press inc, 2011) Dulger, Ahmet Cumhur; Kemik, Ozgur; Selvi, Fatih; Begenik, Huseyin; Emre, Habib; Erdur, Fatih Mehmet
Budd-Chiari syndrome (BCS) is a hepatic venous outflow block generally resulting from disorders affecting hepatic venous system. Elevated hepatic venous pressure results in portal hypertension. BCS may also cause hepatic encephalopathy. Echinococcus multilocularis is a tapeworm parasite and the natural course of the disease may affect liver parenchyma as well as hepatic venous tree. It is the most terrible parasitic disease of the liver and is easily confused with hepatic malignancies. Albendazole therapy may suppress disease progression. Alveolar echinococcosis of the liver rarely causes Budd-Chiari syndrome-related hepatic encephalopathy (HE). We report a rare case of alveolar echinococcosis-related BCS with HE, who was successfully managed by rifaximin and albendazole.
Hydrocephaly Secondary To Central Vein Thrombosis in a Hemodialysis Patient
(Professional Medical Publications, 2012) Emre, Habib; Soyoral, Yasemin Usul; Erdur, Fatih Mehmet; Begenik, Huseyin; Sayin, Refah
Neurological disorders can be observed in hemodialysis patients due to uremic encephalopathy, electrolyte imbalance, infection, medications, glucose intolerance, hypoxia and psychiatric disorders. We present a case of hydrocephalus consequent to central vein thrombosis that is rarely seen in an adult hemodialysis patient and which causes neuro-psychiatric symptoms.
Non-Secretory Multiple Myeloma in a Hemodialysis Patient With Hypercalcemia
(Galenos Yayincilik, 2012) Erdur, Fatih Mehmet; Soyoral, Yasemin Usul; Emre, Habib; Begenik, Huseyin; Tasdemir, Mehmet; Erkoc, Reha
The Prevalence of Fabry Disease in Patients With Chronic Kidney Disease in Turkey: The Turkfab Study
(Karger, 2016) Turkmen, Kultigin; Guclu, Aydin; Sahin, Garip; Kocyigit, Ismail; Demirtas, Levent; Erdur, Fatih Mehmet; Ortiz, Alberto
Background/Aims: Fabry disease is a treatable cause of chronic kidney disease (CKD) characterized by a genetic deficiency of a-galactosidase A. European Renal Best Practice (ERBP) recommends screening for Fabry disease in CKD patients. However, this is based on expert opinion and there are no reports of the prevalence of Fabry disease in stage 1-5 CKD. Hence, we investigated the prevalence of Fabry disease in CKD patients not receiving renal replacement therapy. Methods: This prospective study assessed a-galactosidase activity in dried blood spots in 313 stage 1-5 CKD patients, 167 males, between ages of 18-70 years whose etiology of CKD was unknown and were not receiving renal replacement therapy. The diagnosis was confirmed by GLA gene mutation analysis. Results: Three (all males) of 313 CKD patients (0.95%) were diagnosed of Fabry disease, for a prevalence in males of 1.80%. Family screening identified 8 aditional Fabry patients with CKD. Of a total of 11 Fabry patients, 7 were male and started enzyme replacement therapy and 4 were female. The most frequent manifestations in male patients were fatigue (100%), tinnitus, vertigo, acroparesthesia, hypohidrosis, cornea verticillata and angiokeratoma (all 85%), heat intolerance (71%), and abdominal pain (57%). The most frequent manifestations in female patients were fatigue and cornea verticillata (50%), and tinnitus, vertigo and angiokeratoma (25%). Three patients had severe episodic abdominal pain attacks and proteinuria, and were misdiagnosed as familial Mediterranean fever. Conclusions: The prevalence of Fa bry disease in selected CKD patients is in the range found among renal replacement therapy patients, but the disease is diagnosed at an earlier, treatable stage. These data support the ERBP recommendation to screen for Fabry disease in patients with CKD of unknown origin. (C) 2016 The Author(s) Published by S. Karger AG, Basel
Serum Paraoxonase Activity and Oxidative Stress in Patients With Adult Nephrotic Syndrome
(Elsevier Ireland Ltd, 2011) Soyoral, Yasemin Usul; Aslan, Mehmet; Emre, Habib; Begenik, Huseyin; Erdur, Fatih Mehmet; Turkel, Adnan; Erkoc, Reha
Objective: It has been shown that low paraoxonase-1 (PON1) activity is associated with a risk of an early development of atherosclerosis. In the present study, we investigated serum paraoxonase, and arylesterase activities and oxidative stress in patients with adult nephrotic syndrome (NS). In addition, we examined the relationship between these measurements and atherosclerosis. Methods: Twenty-one patients with NS and 21 healthy controls were enrolled in the study. Serum basal and salt-stimulated paraoxonase activities, arylesterase activity, lipid hydroperoxide (LOOH) and total thiol (SH) levels were measured. Results: Serum basal and salt-stimulated paraoxonase activities, arylesterase activity and total SH levels were significantly lower in patients with NS than in controls (p < 0.05, p < 0.05, p < 0.01 and p < 0.05, respectively), whereas LOOH levels were significantly higher (p < 0.05). Serum LOOH levels were significantly correlated with total-SH levels in patients with NS (r = -0.467; p < 0.01). Moreover, proteinuria levels were significantly correlated with serum LOOH levels (r = 0.397; p < 0.01), whereas no correlation was found among serum paraoxonase activity, arylesterase activity and total-SH levels in NS patients (p > 0.05). Conclusions: We concluded that oxidative stress is increased, while serum PON1 activity is decreased in patients with adult NS. In addition, these results indicate that lower PON1 activity is associated with an oxidant-antioxidant imbalance that may contribute to atherosclerosis in adult patients with NS. (C) 2011 Elsevier Ireland Ltd. All rights reserved.